KT-531 a HDAC Inhibitor Exhibiting Therapeutic Potential in T‑Cell Prolymphocytic Leukemia. KT-531 exhibited higher potency in T-PLL compared to other hematological cancers. KT-531 displayed strong HDAC6 inhibitory potency and selectivity, on-target biological activity, and a safe therapeutic window in nontransformed cell lines. In primary T-PLL patient cells, where HDAC6 was found to be overexpressed, KT-531 exhibited strong biological responses, and safety in healthy donor samples. Notably, combination studies in T-PLL patient samples demonstrated KT-531 synergizes with approved cancer drugs, bendamustine, idasanutlin, and venetoclax.
MedKoo Cat#: 464864
Name: KT-531
CAS#: 2490284-18-7
Chemical Formula: C17H14F4N2O4S
Exact Mass: 418.0610
Molecular Weight: 418.36
Elemental Analysis: C, 48.81; H, 3.37; F, 18.16; N, 6.70; O, 15.30; S, 7.66
The following data is based on the product molecular weight 418.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |